Kevin Krenitsky is a corporate strategist, and turnaround expert with significant experience growing and transforming venture-capital startup, privately held, and publicly traded organizations. Dr. Krenitsky has served as President at OpGen. At Foundation Medicine, Dr. Krenitsky was influential in taking the company from start-up to a $1 billion IPO in 2 years and later a 1.2B strategic investment by Roche. Dr. Krenitsky was also responsible for leading one of the most successful commercial launches (FoundationOne™) in the history of molecular diagnostics. Dr. Krenitsky has achieved a Doctor of Medicine degree from Jefferson Medical College in Philadelphia, PA, a Bachelor of Science degree in Business Management from the University of Scranton, PA, and is a Licensed Medical Doctor in the Commonwealth of Pennsylvania & Massachusetts.
Patrick Wen is Director of the Center For Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. Dr. Wen is also chair of the Dana-Farber/Harvard Cancer Center Neuro-Oncology Clinical Trials Committee and principal or co-investigator of many ongoing clinical protocols. Dr. Wen's clinical research focuses on targeted molecular therapies and anti-angiogenic therapies for gliomas, meningiomas, and brain metastases. He serves on numerous national and international committees, including the NCI Developmental Therapeutics and the Cancer Diagnostic and Treatment SBIR Study Sections and co-chairs the American Brain Tumor Consortium New Agents Committees. He is Editor-in-Chief for the Journal of Neuro-Oncology and on the editorial board of Clinical Cancer Research. He is Chair of the Medical Advisory Board for the National Brain Tumor Society.